Chinese biotech developing oncology and immunology biologic drugs, with multiple licensing deals with Western pharma.
Chinese biotech developing oncology and immunology biologic drugs, with multiple licensing deals with Western pharma.
Sells its medicines mainly to Chinese hospitals, where inclusion on the national reimbursement list trades lower prices for much higher volumes, with its PD-1 cancer drug sintilimab (Tyvyt) the long-time core. It added a second leg in 2025 with mazdutide, a weight-loss drug licensed from Eli Lilly for China and approved there.
In one line: A Chinese biologics-focused biotech with Eli Lilly and other global partnerships.
Moat: narrow (IP / patents, process know-how). In-house biologics manufacturing and a broad, partnered pipeline of patented drug candidates.
Headquarters: Suzhou, China · Founded: 2011 · Employees: 7,502
Size Innovent Biologics (1801.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $18.9B, the 89th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$83.50 on 18 Nov 2026.
Performance Over six months the shares gained 4.4%, against +4.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 42.6% over the last twelve months (peer median +24.9%); the operating margin is 16.9% (peer median 20.8%).
Valuation It trades at 52.3× forward earnings against a peer median of 23.8× (4th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 61.7 points above its cost of capital (8.3% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$17.6B | HK$14.1B | HK$10.2B | HK$6.86B | HK$5.30B |
| Revenue growth | — | +38% | +49% | +29% | — |
| Gross profit | HK$15.1B | HK$12.2B | HK$8.58B | HK$5.60B | HK$4.22B |
| EBITDA | HK$3.72B | HK$2.84B | HK$613M | -HK$689M | -HK$2.74B |
| Net income | HK$1.41B | HK$882M | -HK$103M | -HK$1.14B | -HK$2.53B |
| Free cash flow | HK$14.6B | HK$10.8B | HK$863M | -HK$878M | -HK$3.27B |
| Capital expenditure | HK$703M | HK$741M | HK$1.85B | HK$1.53B | HK$1.59B |
| Total debt | n/a | HK$3.14B | HK$3.01B | HK$3.99B | HK$3.62B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Jiangsu Hengrui Pharmaceuticals 1276.HK | $44.9B | -24% | +11% | 27% | 28.1× | 9.1% |
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% |
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | $3.49B | -38% | +36% | -14% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1801.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | +6.1% | 5th lowest of 21 |
| 6-month return | +4.4% | +4.9% | 11th highest of 21 |
| Distance from 52-week high | -25.9% | -8.4% | 4th lowest of 21 |
| Revenue growth (TTM) | +42.6% | +24.9% | 8th highest of 21 |
| Operating margin | 16.9% | 20.8% | 8th lowest of 21 |
| Forward P/E | 52.3× | 23.8× | 4th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 11.6% | 7.9% | 8th most demanding of 18 |
| Growth delivered (Del g) | +26.8% | +12.5% | 5th highest of 18 |
| Hurdle (Req g minus delivered) | -15.2 pp | -10.8 pp | 8th least demanding of 18 |
| ROIC minus cost of capital | +61.7 pp | +7.2 pp | 3rd highest of 21 |
| EV / EBITDA | 34.3× | 18.5× | 4th most expensive of 17 |
| Net debt / EBITDA | -5.5× | 0.5× | least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% | +26.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% | +11.3% |
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% | +49.8% |
| Shionogi & 4507.T | Japan | $17.6B | +3% | +46% | 29% | 11.8× | 0.2% | +11.0% |
| Ascendis Pharma A/S ASND | United States | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% | +152.4% |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 17.7× | -3.8% | +18.6% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |